Two Cases of Humoral Hypercalcemia of Malignancy in Metastatic Cholangiocarcinoma.
- Author:
Seungtaek LIM
1
;
Jungwoo HAN
;
Kyeong Hye PARK
;
Won Jai JUNG
;
Yong Kang LEE
;
Ara CHOI
;
Young Jae KIM
;
Jong Chan LEE
;
Hye Jin CHOI
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. choihj@yuhs.ac
- Publication Type:Case Report
- Keywords:
Hypercalcemia;
Cholangiocarcinoma;
Parathyroid hormone-related protein
- MeSH:
Abdominal Pain;
Calcium;
Chemoradiotherapy;
Cholangiocarcinoma;
Cisplatin;
Deoxycytidine;
Disease Progression;
Fluorouracil;
Humans;
Hypercalcemia;
Male;
Paraneoplastic Syndromes;
Parathyroid Hormone-Related Protein;
Prognosis;
Recurrence;
Capecitabine
- From:Cancer Research and Treatment
2013;45(2):145-149
- CountryRepublic of Korea
- Language:English
-
Abstract:
Humoral hypercalcemia of malignancy (HHM) is rarely associated with cholangiocarcinoma (CC), and represents dismal prognosis. A 63-year-old male was admitted for evaluation of an intrahepatic mass. He was diagnosed with HHM associated with locally advanced CC. As the tumor responded to the concurrent chemoradiotherapy with capecitabine and cisplatin, serum calcium level was normalized. However, according to the disease progression, he suffered recurrence of HHM and he expired approximately one year after initial diagnosis. A 68-year-old male who presented with abdominal pain was diagnosed with metastatic CC. After the eighth cycle of gemcitabine and cisplatin, progression of the disease was found with HHM. He was treated with the best supportive care, until his demise approximately one month after the diagnosis of HHM. We report on two cases of HHM associated with CC that demonstrate strong correlation between hypercalcemia and disease burden.
